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The objective of improving health is intimately 
associated with preventing and delaying age-related 
diseases. Nutritional and pharmacological approaches 
aimed at retarding aging are uncovering mechanisms, 
whose definitive roles in cell and tissue physiology need to 
be defined. In this article we hypothesize that peroxisome 
proliferator activated receptor (PPAR)-modulation is a 
pivotal process that underlies the association between 
mitochondria and the renin-angiotensin system (RAS) in 
aging. This hypothesis is based on several lines of evidence 
suggesting that: a) mitochondrial function and oxidant 
production are active participants in the aging process; b) 
PPARs, by regulating mitochondrial function and 
uncoupling proteins (UCP), seem to play a major role in the 
age-retarding effects of caloric restriction; c) RAS 
inhibition delays the deleterious effects of aging and also 
upregulates PPARs; and d) a number of physiological and 
molecular events that occur in experimental caloric 
restriction, and experimental and clinical RAS inhibition, 




The inhibition of the renin-angiotensin system 
(RAS), a broadly used therapeutic strategy to counteract 









unrelated to the lowering of blood pressure (1-4). The 
mechanisms responsible for those beneficial effects are not 
completely characterized. We have extensively investigated 
the effects of RAS inhibition on mitochondrial function, 
mitochondrial oxidant production and oxidative damage to 
mitochondria (5-8). Based on both our findings and 
published evidence, in this review we will discuss the 
hypothesis of a pivotal role of peroxisome proliferator 
activated receptor (PPAR)-modulation in the preservation 
of mitochondrial function to explain the beneficial health 
effects of RAS inhibition. Considering the relevant 
participation of mitochondria (9-12) and the RAS (13-15) 
in both, aging and aging-associated diseases, we will focus 
most of our discussion on aging. 
 
3. OXIDANTS AND MITOCHONDRIA IN THE 
AGING PROCESS 
 
3.1. Oxidant species, antioxidants, and oxidative stress 
Reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are generic terms that include 
byproducts of oxygen metabolism continuously generated 
in aerobic organisms (10, 16). ROS and RNS can react with 
other biologically relevant molecules (e.g. lipids, proteins, 
and nucleic acids) leading to cell and tissue damage (17). 
Aerobic organisms are endowed with an assorted group of 
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molecules, referred to as antioxidants, to control oxidant 
production and prevent cell and tissue damage (18). 
Antioxidants essentially include both, low molecular weight 
compounds able to scavenge or deactivate oxidants, and 
enzymes that catalyze the decomposition of oxidants. In 
addition, non-enzyme proteins (uncoupling proteins, 
thioredoxin, histones, etc.) as well as other biomolecules (plant 
polyphenols, etc.) can afford antioxidant protection to 
biological systems by mechanisms that do not involve direct 
oxidant reduction (18). However, under certain circumstances, 
control over ROS and RNS levels is lost, resulting in oxidative 
stress. Oxidative stress is a concept defined by Sies (19) as “an 
imbalance between oxidants and antioxidants in favor of the 
oxidants, potentially leading to damage”. 
 
3.2. Mitochondria as sources and targets of reactive 
oxygen species and reactive nitrogen species 
Mitochondria are essential for the maintenance of 
aerobic life not only as sources of energy, but also by 
regulating Ca2+ homeostasis (20), tissue O2 gradients (21), 
cell apoptosis (22), and intracellular signaling (23). 
However, the partial reduction of O2 by the mitochondrial 
respiratory chain components results in an undesirable 
production of oxidants. Thus, mitochondria are a major 
source of ROS, and are themselves targets of ROS-
mediated damage. Mitochondria produce superoxide anion 
(O2-) by univalent reduction of O2 (10) at two sites of the 
electron transport chain (24, 25), and hydrogen peroxide 
(H2O2) as the product of the enzymatic reduction of O2- by 
superoxide dismutase. Both, O2- and H2O2, are ROS that 
can initiate free radical chain reactions leading to the 
generation of other oxidants, and potentially to a situation 
of oxidative stress. Further reduction of H2O2 to water is 
catalyzed by the enzymes catalase and glutathione 
peroxidase. If the targets of ROS are molecules that can 
propagate free radical reactions (e.g. lipids), damage can 
extend inside the cells leading to the oxidation of other 
relevant molecules (proteins, nucleic acids, etc.). Nitric 
oxide (NO) is an essential signaling molecule that is 
additionally involved in ROS-mediated oxidations. Nitric 
oxide is produced by the oxidation of L-arginine to L-
citrulline, a reaction catalyzed by several nitric oxide 
synthase (NOS) isoforms (26). By diffusion-limited 
reaction with O2-, NO yields peroxynitrite (ONOO-), a very 
strong oxidant. Nitric oxide, peroxynitrite, and other 
oxidant species derived from NO are termed RNS. The 
existence of a constitutive mitochondrial activity of NOS 
(mtNOS) (27, 28) underlies the biological relevance of NO 
generation in mitochondria. 
 
Current evidence supports a prominent role for 
ROS and RNS in both, the decline of mitochondrial 
function and the increase in mitochondrial DNA oxidation 
that occurs in various tissues upon aging (29-33). 
 
To minimize the production of ROS and RNS, 
mitochondria drive O2 reduction to water with very high 
efficiency (accounting for about 97-98% of the O2 respired) 
(10). Additionally, to control the damage inflicted by the 
partial reduction of the remaining 2-3% of respired O2, 
mitochondria are well equipped with a battery of enzymes 
that metabolize ROS, including manganese superoxide 
dismutase (Mn-SOD), catalase, and glutathione peroxidase. 
Other enzymes, such as glutathione reductase and 
thioredoxin reductase, that catalyze the NADPH-dependent 
reduction of disulfides, can be also considered part of the 
mitochondrial antioxidant defenses. Finally, there are other 
mitochondrial proteins that can limit the production of 
oxidants, e.g. uncoupling proteins (UCP). 
 
Recently, the concept has emerged that 
mitochondria not only receive signals from elsewhere in the 
cell, but they also generate signaling molecules (23). For 
example, it has been demonstrated that H2O2 and NO 
diffuse from the mitochondria into the cytosol modulating 
redox-sensitive signaling pathways (34, 35). 
 
In summary, mitochondria are not only 
recognized as the main sources of cellular energy, but also 
as organelles that by driving ROS and RNS generation play 
other key roles in the regulation of cell functions and 
survival. 
 
3.3. Mitochondria and peroxisome proliferator 
activated receptors 
PPARs are nuclear transcription factors that 
regulate the expression of a number of genes related to lipid 
metabolism and energy homeostasis (36). PPAR isoforms 
are members of the nuclear hormone receptor superfamily 
of transcription factors, and include PPAR-alpha, PPAR-
beta, and PPAR-gamma. Upon ligand-binding, PPARs 
heterodimerize with 9-cis-retinoic acid receptor (RXR), 
thereby acquiring the ability to recognize and bind 
peroxisome proliferator-responsive elements (PPRE) in 
target genes. All three PPAR subtypes bind the same PPRE 
(37) and can interact with either RXR-alpha, beta, or gamma. 
Most of the PPAR ligands that have been studied are synthetic, 
and a limited number are of endogenous origin (38). 
 
PPAR-alpha is expressed highly in liver, heart 
and skeletal muscle (39). At the mitochondrial level, 
activation of PPAR-alpha results in an increased expression 
of many nuclear genes associated with mitochondrial 
function, including those involved in fatty acid beta-
oxidation (38), mitochondrial proton leak (40, 41), and 
those encoding antioxidant enzymes, i.e. Mn-SOD and 
catalase (42). PPAR-gamma, which is highly expressed in 
adipocytes, is involved in adipocyte differentiation and 
controls the expression of lipid storage genes. Another 
relevant function of PPAR-gamma is the promotion of insulin 
sensitivity (43). PPAR-delta is involved in the regulation of 
fatty acid catabolism, metabolic rate and proliferation of 
mitochondria mainly in skeletal muscles (44). 
 
3.4. Aging, mitochondria, and peroxisome proliferator 
activated receptors  
The participation of mitochondria in the 
continuous production of ROS and RNS supports the 
mitochondrial free radical theory of aging as formulated in 
1979 by Chance et. al. (10) as an extension of the more 
general free radical theory of aging (9, 12, 45). Concerning 
aging and mitochondrial ROS generation, it was recently 
reported that the mitochondria targeted overexpression of 
catalase, extends the median and maximum lifespan in 
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mice (46). This life extension concurred with decreases in 
oxidant damage to DNA, mitochondrial H2O2 production, 
aconitase inactivation, and in the accumulation of 
mitochondrial DNA deletions (46), suggesting a link 
between mitochondrial ROS generation, mitochondrial 
damage, and aging. 
 
In addition, age-associated diseases, including 
hypertension, diabetes, cancer, and cardiovascular 
pathologies, are often accompanied by alterations in lipid 
metabolism, which is largely modulated by mitochondrial 
activity. The involvement of PPAR-alpha and PPAR-
gamma in the above mentioned diseases is underscored by 
studies showing the beneficial effects of PPAR-alpha and 
PPAR-gamma agonist administration (47-51). Aging is 
associated with a decline in the expression of PPAR-alpha 
and gamma (52). In addition, in skeletal muscle cells, 
increased ROS production was shown to downregulate 
PPAR-alpha mRNA (53). In this setting, a body of 
evidence support a strong association between PPAR 
activities and the aging process (54). 
 
Relationships among PPARs, oxidative stress, 
and aging are supported by studies showing that ligand 
activated PPAR-alpha can suppress the age-dependent 
augmentation of both, oxidative stress and oxidant-
dependent NF-kappa B activation (55). These results 
suggested that the prooxidant state displayed by cells of 
aged animals may be related to the age-related decline in 
PPAR-alpha expression (34). Furthermore, PPAR-alpha 
activators upregulate uncoupling protein-2 (UCP-2) 
expression (41), and treatment with PPAR-gamma agonists 
increases UCP-2 mRNA levels in adipose and skeletal 
muscle cells (56, 57). 
 
UCPs are proton gradient-dissipating 
mitochondrial proteins that seem to act in both, the 
regulation of fatty acid and glucose oxidation (58, 59), and 
the control of O2- generation by mitochondria (58-60). 
PPAR-gamma activation increased endothelial NO 
production in bovine aortic endothelial cells (61). The 
participation of NO as a downstream effector of PPARs 
activation has also been observed in animal models. In rat 
kidney, activation of PPAR-alpha promoted Na+ excretion 
by increasing NO generation (62). In hypertensive rats, the 
cardioprotective effects afforded by PPAR-alpha activation 
were mediated by an increase in NO production and/or an 
inhibition of NADPH oxidase activity (63). 
 
The above evidence suggests that PPAR-alpha, 
through mechanisms involving UCP-2, may lower 
mitochondrial oxidant production, and, consequently, retard 
the aging process as well the development of age-
associated diseases.  
 
4. THE RENIN-ANGIOTENSIN SYSTEM, 
MITOCHONDRIA, AND AGING 
 
4.1. The renin-angiotensin system and the cellular 
generation of ROS and NO 
In the classical view, the RAS was exclusively 
recognized by its circulating actions as a regulator of 
systemic blood pressure and renal electrolyte balance. After 
the discovery of RAS gene expression and function in a 
variety of tissues, a role for RAS as regulator of organ 
functions (autocrine) was acknowledged. These local tissue 
effects of RAS are a subject of current research, and appear 
to be distinct from circulating RAS actions (64). The major 
components of both, circulating and tissue RAS, include 
the polypeptides angiotensinogen, angiotensin I (Ang-I) 
and angiotensin II (Ang-II). Ang-I is the product of 
enzymatic angiotensinogen cleavage by renin, and Ang-II 
is the product of Ang-I cleavage by Ang-I-converting 
enzyme (ACE) (65). Ang-II, the main effector of the RAS, 
is responsible for vasoconstriction and Na+ retention (66). 
Ang-II is also a pro-inflammatory and a pro-fibrotic agent 
(67, 68). 
 
Abundant evidence supports the notion that both, 
the increased generation of cellular ROS, and the activation 
of redox-sensitive signaling cascades are critical events 
involved in Ang-II actions (69). Many of the functional 
effects of Ang-II are mediated via the angiotensin-II-
receptor 1 (AT1). Ang-II binding to AT1 triggers 
intracellular O2- production by NAD(P)H oxidase 
activation (70, 71), and also as a result of endothelial NOS 
(eNOS) uncoupling (72). On account of O2- production, 
cellular NO steady state level may be compromised due to 
the reaction of NO with O2- to generate peroxynitrite. As a 
final consequence of this series of events, and as it has been 
observed in a variety of cell types (72, 73), Ang-II 
promotes the production of both, ROS and RNS, and 
reduces NO availability. Relevant to endothelial cell NO 
production, it has been demonstrated that bradykinin, 
another ACE substrate, binds to BK1 and BK2 plasma 
membrane receptors, thereby activating endothelial NOS 
(eNOS) (74). 
 
Under normal physiological conditions, Ang-II-
mediated ROS and RNS production, and the resulting 
stimulation of redox-sensitive signaling pathways, are 
closely regulated (73). However, under conditions leading 
to overactivation of the RAS, such as hypertension, 
diabetes (75, 76) and normal aging (77-80), Ang-II-
dependent oxidant generation may become a significant 
contributor to cell oxidation and tissue damage. In vascular 
smooth muscle cells from spontaneously hypertensive rats 
(SHR), Ang-II was shown to enhance the activation of NF-
kappa B and AP-1, two transcription factors modulated by 
the cellular redox status (81). In addition, it was shown that 
antioxidants and antioxidant enzymes inhibit the regulatory 
effects of Ang-II on Ras/Raf/ERK and AP-1 signaling 
pathways (82, 83).  
 
4.2. The renin-angiotensin system and mitochondria 
The relationships between RAS and mitochondria 
started to gain attention when it became evident that, by 
prompting ROS formation, RAS effectors can activate 
redox-sensitive transcription factors involved in the 
modulation of mitochondrial function. 
 
A causative link between RAS activation and 
alteration of mitochondrial function is supported by the 
observation that in mice, acute (24 h) and long-term (14 d) 
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Ang-II infusion leads to decreased cardiac expression of 
mitochondrial electron transfer chain and Krebs-TCA cycle 
genes (84). In the short term treatment, Ang-II also 
promoted the depression of mitochondrial metabolism and 
Mn-SOD gene, and induced the expression of genes for 
proteins that protect against oxidative stress, such as 
thioredoxin, glutaredoxin and transferring receptor 1 (84). 
These effects are in line with previous observations that 
indicated the participation of Ang-II in the depression of 
mitochondrial energy metabolism (85-87). In addition, 
recent findings show that Ang-II stimulates mitochondrial 
ROS production associated with the reduction of 
mitochondrial membrane potential (88). 
 
In addition, there is some evidence supporting a 
direct interaction between Ang-II and nuclear and 
mitochondrial components. A number of studies have 
produced evidence for the existence of nuclear AT1-like 
AngII receptors in rat liver and spleen cells. In studies 
using 125I-labeled Ang-II, the presence of Ang-II was 
shown in nuclei and mitochondria of heart, brain and 
smooth muscle cells (89, 90). Treatment of isolated rat liver 
nuclei with Ang-II stimulated the transcription of specific 
genes (91, 92). In addition AT1 receptor blockers (losartan) 
inhibit Ang-II binding to nuclear receptors in rat 
hepatocytes (91, 93). The inhibition of Ang-II binding to 
nuclear receptors by losartan might suggest this possibility. 
In rat adrenal cortex, immunocytochemical and 
biochemical evidence indicates the presence of renin, 
angiotensinogen and ACE within intramitochondrial dense 
bodies of the zona glomerulosa (94). 
 
Concerning cell signaling modulation by 
mitochondria, c-Jun NH2-terminal kinase (JNK) is both, a 
downstream target of AT1 dependent signaling (95) and a 
regulator of AP-1 activity. Since AP-1 regulates 
cytochrome c expression (96), it was suggested that JNK 
may facilitate changes in the mitochondrial content of 
cytochrome c in response to Ang-II (97). Adding to 
previous evidence that supports the participation of the 
RAS in mitochondrial function responses, the modulation 
of heart and liver mitochondrial NOS activity and H2O2 
production by the ACE inhibitor enalapril has been 
observed in rats (98, 99). Moreover, a recent study showed 
that the expression of genes related to fatty acid beta-
oxidation, mitochondrial proton-electron coupling, and 
oxidative phosphorylation were up-regulated in captopril-
treated diabetic animals, suggesting that RAS inhibition 
with ACE inhibitors may protect the myocardium by 
enhancing energy supply (100).  
 
4.3. The renin-angiotensin system and peroxisome 
proliferator activated receptors  
Ang-II infusion was shown to downregulate 
PPAR-alpha and PPAR-gamma mRNA and protein in 
apolipoprotein E-deficient (apoE-KO) mice (101). This 
downregulation occurred in parallel with the activation of 
NF-kappaB and NF-kappaB-mediated proinflammatory 
genes (101). Conversely, activators of PPAR-alpha and 
PPAR-gamma antagonize the proliferative, inflammatory 
and oxidant-generating actions of Ang-II both, in vivo and 
in vitro (43, 102, 103). In this context, it is possible to 
hypothesize that RAS inhibition lowers oxidant production 
not only by blocking Ang-II activation of NADPH-oxidase, 
but also by regulating the expression of PPARs. In this 
regard, enalapril was shown to upregulate PPAR-alpha and 
PPAR-gamma while displaying antiatherogenic and anti-
inflammatory effects in mice (104). Two AT1-receptor 
blockers, irbesartan and telmisartan, were identified as 
activators of PPAR-gamma (105, 106). Recently, a product 
of the hepatic metabolism of losartan (EXP3179) was 
identified as a partial PPAR-gamma agonist, suggesting 
that some of the AT1-receptor blockers can mediate AT1-
receptor independent effects (107). 
 
4.4. The renin-angiotensin system and aging  
Based on evidence suggesting the involvement of 
mitochondria in the aging process, we have investigated 
how the modulation of the RAS can affect mitochondrial 
dysfunction associated with aging and aging-associated 
diseases. In one study, we set forth to investigate whether 
long-term RAS inhibition, either by treatment with an ACE 
inhibitor (enalapril) or with an AT1 receptor blocker 
(losartan) might attenuate structural and functional changes 
that occur in mitochondria upon aging. Supporting our 
hypothesis, kidney mitochondria from old rats (22 month-
old) that were treated for 8 months with enalapril or 
losartan, showed an improved capacity for energy 
production, a lower rate of H2O2 production, a higher 
activity of mtNOS, and a higher content of UCP-2, 
compared to mitochondria isolated from untreated old rats 
(8) (Figure 1). In the same study we observed a general 
improvement in mitochondrial number and structure. 
Proximal tubular epithelial cells from the enalapril- or 
losartan-treated old rats showed a higher number of 
mitochondria, a better definition of mitochondrial cristae, 
and a lower number of osmiophilic bodies (probably 
derived from lipid oxidation). Furthermore, both treatments 
(enalapril or losartan) prevented the alteration of 
mitochondrial distribution inside proximal tubular cells that 
was observed in untreated old rats, and attenuated 
glutathione oxidation in renal tissue (8). These results 
indicate that RAS inhibition, regardless of how it is 
implemented, protects mitochondrial components and 
function from certain effects of aging. 
 
A body of evidence supports the concept that 
vascular Ang-II presence and responsiveness increase with 
aging (78-81), and that the RAS may contribute to the 
development of age-related tissue damage (108). Inhibition 
of the RAS, either with ACE inhibitors or AT1 receptor 
blockers, can attenuate several effects of aging in rodents 
(109, 110). Numerous studies have shown that RAS 
inhibition prevents different aspects of renal, cardiac, 
vascular, and behavioral changes that are associated with 
the aging process in rodents (111). 
 
The potential associations between RAS 
inhibition and PPAR modulation in aging are congruent 
with: i) the relatively high levels of Ang-II present in aged 
organisms (77-80); and ii) the prevention of age-dependent 
decreases in UCP content that occur secondary to RAS 
inhibition (8). Furthermore, the stimulation of PPAR-alpha 
dependent transcription of nuclear genes involved in




Figure 1. Enalapril and losartan treatments make mitochondrial functions in old rats resemble those of young rats. Respiratory 
control (respiratory state 3/ respiratory state 4), ADP/O, H2O2 production, Mn-SOD activity, nitric oxide synthase (mtNOS) 
activity, and UCP-2 content, in kidney mitochondria from 22-month old untreated rats (Old); 22-month old rats treated with 
enalapril (Enal) or losartan (Los) during 8 months; and 4-month old untreated rats (Young). *p< 0.05 vs. Old; #p< 0.01 vs Old, 
Enal, and Los. Data taken from (8). 
 
mitochondrial fatty acid oxidation would enhance the 
generation of electron donors for the respiratory chain, thus 
suppressing the age-dependent deficit of ATP production. 
This is supported by our observation of an increase in 
mitochondrial ADP/O ratios following RAS inhibition in 
aging rats (8). 
 
4.5. Renin-angiotensin system inhibition in hypertension 
and diabetes 
Pharmacological RAS inhibition, either with 
ACE inhibitors or AT1 receptor blockers, is widely used in 
patients with hypertension, cardiovascular disease and 
diabetes (112-114). In these pathological states, the cardiac 
and renal benefits of RAS inhibition go beyond its blood 
pressure lowering effects (112, 113, 115) suggesting that 
ACE inhibitors and AT1 receptor blockers can exert tissue 
actions that are not associated with their hemodynamic 
effects. 
 
Incidentally, both, mitochondrial dysfunction and 
RAS have been independently implicated in hypertension 
(116) and diabetes (117). These findings led us to 
investigate whether RAS inhibition might protect 
mitochondria from damage related to both pathological 
conditions. In spontaneously hypertensive rats (SHR), 
treatment with losartan prevented the alterations in kidney 
mitochondrial membrane potential, UCP-2 content, H2O2 
production rate, and in the activities of mtNOS, Mn-SOD, 
and cytochrome oxidase that occurred in untreated SHR 
(118). In rats rendered diabetic by streptozotocin injection, 
losartan protected kidney mitochondria against changes in 
membrane potential, H2O2 production rate, and pyruvate 
content, without lowering plasma glucose content (119). In 
both studies, the administration of amlodipine, a Ca2+ 
channel blocker, reduced blood pressure to an extent 
similar to losartan, but showed no beneficial effects on 
kidney mitochondria alterations. The results obtained in 
these two rat models of hypertension and diabetes, indicate: 
a) a dissociation between blood pressure lowering and the 
improvement of mitochondrial function; and b) the 
involvement of Ang-II-AT1 receptor interaction as a 
relevant step for mitochondrial dysfunction. 
 
5. CALORIC RESTRICTION, AGING, OXIDATIVE 
STRESS, MITOCHONDRIA, AND PEROXISOME 
PROLIFERATOR ACTIVATED RECEPTORS 
 
Caloric restriction, without malnutrition, is one of 
the most consistent interventions to reduce the rate of aging 
in different species. Caloric restriction increases mean and 
maximum lifespan, and retards both, the decay of 
physiological functions, and the appearance of diseases 
associated with aging, such as hypertension, diabetes, 
nephropathy, cardiovascular disease, and cancer (120-124). 
 
Reduction in metabolic rate represents one 
explanation for the beneficial effects of caloric restriction 
observed in different animal species. This reduction leads 
to lower O2 consumption, ROS generation (125), and 
oxidatively damaged proteins (126-128), lipids (129-131), 
and DNA (32, 33, 132, 133) than do ad libitum fed animals. 
With regard to its effects on mitochondria, long-term 
caloric restriction lowers the rate of mitochondrial H2O2 
production and decreases the levels of mitochondrial DNA 
oxidative damage in rat liver, heart, skeletal muscle and 
brain (32, 33, 133, 134). In addition, caloric restriction was




Figure 2. Scheme of the physiological actions elicited by caloric restriction and RAS inhibition and their impact on aging, having 
peroxisome proliferator activated receptors (PPARs) as central players. Our hypothesis of PPAR participation in the RAS-
mediated retardation of aging is developed based on the converging effects of caloric restriction and RAS inhibition, and on the 
effects of RAS inhibition on mitochondrial function and PPAR modulation. 
 
shown to increase the expression of UCP-2 in mice and in 
humans (135, 136), which may explain the effects of 
dietary manipulation on the reduction of mitochondrial 
H2O2 production. Analogous antioxidant and protective 
effects were observed in different animal species as well as 
in different tissues and cells (31). These observations 
emphasize the relevance of mitochondria and oxidative 
stress in the aging process. 
 
Recent evidence suggests that PPARs may play 
an important role in the delay of aging caused by dietary 
restriction (54). In this context, PPAR nuclear protein, 
mRNA level, and DNA binding activity were shown to 
decrease with age, whereas caloric restriction blunted these 
reductions (52). Alternatively, using microarray 
technology, PPAR target genes were shown to be 
upregulated early and intensely in the livers of calorie-
restricted mice (137).  
 
6. RENIN-ANGIOTENSIN SYSTEM INHIBITION 
AND CALORIC RESTRICTION, TWO STRATEGIES 
CONVERGING AT BIOLOGICAL EFFECTS THAT 
INCLUDE PEROXISOME PROLIFERATOR 
ACTIVATED RECEPTORS 
 
Considering that PPARs seem to play a major 
role in the age-retarding effects of caloric restriction, and 
that RAS inhibition has been shown to retard aging and to 
upregulate PPARs, we hypothesize that the converging 
effects displayed by both interventions are mediated by the 
maintenance of adequate levels of PPAR protein/activity 
(Figure 2). This concurrence is supported by a number of 
physiological and pathological conditions that are affected 
in a similar manner when RAS inhibition or caloric 
restriction, are studied in both humans and animal models. 
The converging effects include: i) retarding the 
manifestations of hypertension (121), diabetes (123, 138), 
nephropathy (120, 139), cardiovascular disease (112, 122), 
and cancer (124, 140, 141); ii) increasing body temperature 
(142, 143) and loss of body weight (144, 145); iii) lowering 
of insulin-like growth factor-I (IGF-1) plasma levels (146-
148); iv) reduction of plasma glucose and insulin levels in 
hypertensive patients (149), and rats (143, 150-152); v) 
improvement of insulin sensitivity in hypertensive patients 
(153-156), which is in agreement with several lines of 
evidence that point to a role for Ang-II in the development 
of insulin resistance (153, 157-159); vi) diminution of 
protein oxidation (126-128), lipid oxidation (129-131), and 
DNA oxidation (32, 33, 132, 133); vii) diminution of the 
rate of mitochondrial H2O2 production in concurrence with 
a decrease of mitochondrial DNA oxidative damage in rat 
liver, heart, skeletal muscle, and brain (32, 33, 133, 134) 
and increased expression of UCP-2 in mice and in humans 
(8, 135, 136). 




Figure 3. Scheme of the molecular pathways relating Ang-II with aging, having PPARs and mitochondria as central players. 
Solid arrows indicate accepted molecular pathways; dashed lines, pathways with experimental support; and dotted lines, 
hypothetical pathways. The mitochondrion is shown in yellow and the nucleus in light blue. Ang-II, angiotensin II; PPAR, 
peroxisome proliferator activated receptor; UCP, uncoupling proteins; mtNOS, mitochondrial nitric oxide synthase; RC, 
respiratory chain; AT1, angiotensin II-receptor 1; NADPHox, NADPH oxidase; TF, transcription factors. For the sake of clarity 
oxidant damage by NO, O2-, H2O2, and ONOO-, as well as other agents in addition to Ca2+, cAMP, and IP3, that are generated 
downstream of AT1 activation are not described in the scheme.  
 
Regarding the effects of RAS inhibition and 
caloric restriction on weight loss, we must add that a 
positive correlation between plasma angiotensinogen levels 
and body mass index was reported in humans (160). 
However, the fact that Ang-II can produce anorexia (145) 
may afford an alternative interpretation for the Ang-II-
mediated weight loss. 
 
7.  CONCLUSIONS AND PERSPECTIVES 
 
By integrating current knowledge in the areas of 
mitochondrial metabolism, RAS, caloric restriction, and 
aging, we have developed a hypothesis in which PPARs 
serve an integrative role as central players. Figure 3 
illustrates the potential molecular mechanisms underlying 
this hypothesis. The proposed mechanisms are based on the 
known activation of the AT1 receptor by Ang-II that leads 
to changes in Ca2+ homeostasis, and cAMP- and inositol 
triphosphate-mediated events, and the subsequent 
activation of NADPH-oxidase which, by generating O2-, 
activates redox-sensitive signaling pathways. The changes 
driven by the activation of the AT1 receptor could also lead 
to the uncoupling of mitochondrial respiration with the 
subsequent increase in O2- generation, and/or to the 
downregulation of PPARs activity, which could result in 
UCP deactivation and increased O2- generation. If Ang-II 
or any of its metabolites could reach the cytosol and the 
mitochondria they might interact with: a) PPARs or UCPs, 
leading to their inactivation; b) mitochondrial components, 
resulting in an increased production of O2- and a decreased 
of NO bioavailability; and/or c) NOS leading to a 
decreased NO generation.  
 
The present hypothesis relating PPARS, 
mitochondria, and the RAS, provides a possible 
explanation for the molecular events that could be involved 
in the well documented effects ascribed to RAS inhibition 
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